Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade - Test2 - elhamkhani - TriplyDB

Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade

Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade

http://www.wikidata.org/entity/Q34426346

about

Identification of valid housekeeping genes for quantitative RT-PCR analysis of cardiosphere-derived cells preconditioned under hypoxia or with prolyl-4-hydroxylase inhibitors Erythropoietin and diabetes mellitus Key fibrogenic mediators: old players. Renin–angiotensin system Renal oxygenation and haemodynamics in acute kidney injury and chronic kidney disease The systemic nature of CKD.HIF-1α activation results in actin cytoskeleton reorganization and modulation of Rac-1 signaling in endothelial cells Silencing of hypoxia-inducible factor-1α gene attenuates chronic ischemic renal injury in two-kidney, one-clip rats.Hypoxia Inducible Factor 1: A Urinary Biomarker of Kidney Disease Renal Oxygenation in the Pathophysiology of Chronic Kidney Disease.Signalling pathways involved in hypoxia-induced renal fibrosis.FIH-1-Mint3 axis does not control HIF-1 transcriptional activity in nucleus pulposus cells.Predictor of poor coronary collaterals in chronic kidney disease population with significant coronary artery disease.Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes.Hemodynamic basis for the limited renal injury in rats with angiotensin II-induced hypertension.Aberrant tubuloglomerular feedback and HIF-1α confer resistance to ischemia after subtotal nephrectomy.The Role of Hypoxia-Inducible Factor/Prolyl Hydroxylation Pathway in Deoxycorticosterone Acetate/Salt Hypertension in the Rat.Induction of hemeoxygenase-1 reduces glomerular injury and apoptosis in diabetic spontaneously hypertensive rats.Interactions between HIF-1α and AMPK in the regulation of cellular hypoxia adaptation in chronic kidney disease.Regeneration in the nervous system with erythropoietin Recent advances in renal hypoxia: insights from bench experiments and computer simulations.Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease.Renal microvascular dysfunction, hypertension and CKD progression.Determinants of kidney oxygen consumption and their relationship to tissue oxygen tension in diabetes and hypertension.Renal Hypoxia in CKD; Pathophysiology and Detecting Methods.HuR and other turnover- and translation-regulatory RNA-binding proteins: implications for the kidney.Renal injury is accelerated by global hypoxia-inducible factor 1 alpha deficiency in a mouse model of STZ-induced diabetes.Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells.Selective tubular activation of hypoxia-inducible factor-2α has dual effects on renal fibrosis.Hypoxia-inducible factor-1α (HIF-1α) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia Cooperative Oxygen Sensing by the Kidney and Carotid Body in Blood Pressure Control.Hypoxia-inducible factor-1α activation improves renal oxygenation and mitochondrial function in early chronic kidney disease.

P2860

Q24624488-35669B82-C820-47A7-ACC0-6B4542905235 Q26777878-3C036D9C-E2F4-43F3-B8AC-55F960F80999 Q26796631-00951921-ACA6-4BFF-8E11-34FD99074ED1 Q26996101-34E41E56-80AC-4838-A96B-775989A806F6 Q30234695-C8E76C43-EEA8-4AF8-AED1-9F2693C071FC Q30565644-1B0DA0D0-A0E5-4CB1-98F1-41512AF8E773 Q33626606-64143E96-BB34-4FB3-B1D8-757B7E37F010 Q33648040-05745763-884B-4831-A18F-F7CC81DBB9AC Q33843362-3FCFCCE0-6558-42BC-89F1-A27535121F19 Q33844658-4DA65AF7-8FA3-40A1-8BF6-64D672F41846 Q33947033-8CA8FCDE-9871-45DD-AF11-158186C2FF9A Q34398468-64DB8AA6-A45E-4D54-A48E-73AC16B1C8E3 Q34505760-403E1AA2-22E4-4F37-8270-937B086FA9BC Q34887803-DCBD5251-D0FD-4939-B91C-AB3113096283 Q35035267-30961FCB-BD95-47DC-849E-0C8DC9B015CE Q35804184-8767A031-6D28-4337-8034-6DC0A937D5CB Q35849510-5DA29E36-4905-45C3-8E3F-46CBB06D4DE2 Q35924532-EE68A979-D856-49B9-92C1-8052C31C7EE3 Q36017602-31835096-2D1C-4DA5-8F8F-544A5758B8A3 Q36247651-E5CF44A2-8240-4E13-8691-C9C3577A6D0E Q37139470-D43BD2E0-CA03-43AE-81AC-99C58D065899 Q37142481-C6FEE24C-8844-4EE6-8240-C02B924EE1B4 Q37618335-634D3934-F098-4221-B5F5-C78ABED75BAA Q37633937-E866E3DF-0624-44A5-B811-9B5003930CA2 Q37653803-8CA53F80-941B-4A0D-8DA7-2EFC3DD9EDC6 Q38178916-38376E01-92F1-4A19-B36B-36262C4E05E9 Q38642880-F612A2DD-7B40-47B5-BB74-8CF8AD20D493 Q39470443-233B467A-5845-4D97-AC4D-FC54B6DB93F7 Q41193367-A85F7088-9B8F-4A41-AB89-AFA9B288277C Q41848385-499134DB-DCC4-4AB3-9A37-34017BDB5C50 Q42372768-F2605696-B605-4A1F-B2E8-7AAA73AB8008 Q46744839-29A1E44C-E7B1-4234-81C3-F7ADA2665005

P2860

Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade

http://www.wikidata.org/entity/Q34426346

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@ast

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@en

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@nl

type

label

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@ast

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@en

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@nl

prefLabel

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@ast

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@en

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@nl

P1433

Q34426346-7414B23C-7E25-4AE0-BA93-8FBAC1803D9B

P1476

Q34426346-2D255A67-C0E9-4F25-A957-6312B6153035

P2093

Q34426346-68CB6F4C-9654-403C-BB28-7CC6183DDE6E

Q34426346-752EFD11-29BD-4D42-90FD-4FB6D3003754

Q34426346-AF2F63B8-E539-4EF5-8608-5CE0343BD6FF

Q34426346-B6890E1B-358F-484F-BCF4-7D69B514B500

Q34426346-E05A1AF1-E437-4184-9E23-E1ACB7614948

Q34426346-E66B795B-53A2-473D-BFF3-85CD6D7F8C89

Q34426346-F1FA35F5-EDA8-41E2-BC8B-8C069FC370FA

P2860

Q34426346-070A9B90-182F-4164-8C3B-D14E6193AD85

Q34426346-0E3CC0A5-EBBA-494E-976E-9A150F520F4B

Q34426346-1057FB16-6A6D-4B87-BE6E-8089C1D3CC43

Q34426346-165F9012-85F3-4019-94AC-1FB5B777815F

Q34426346-1C713445-1CF5-4091-998C-8D54054C540C

Q34426346-1D199DFD-47E8-49CE-9CF1-69A489EEC671

Q34426346-2BF6961A-41FF-4CB6-99E5-1B4C193E27CB

Q34426346-2E3223ED-CDCB-465B-BD1E-0CFED8310A13

Q34426346-42503B8C-F30E-4B2D-BB74-90DDCA31F6E6

Q34426346-44CC54C3-F136-4A6A-9EFB-3357B3A73E16

P304

Q34426346-D2C405DC-9FDC-470E-A3DD-538301536A97

P31

Q34426346-54993A28-144C-40D7-9AD1-1946DAC97F40

P356

Q34426346-973A299C-C9A5-4153-B79B-E60A1D23ACD8

P433

Q34426346-1D001E31-88A6-4D32-B81A-885EDE5AD720

P478

Q34426346-7D29C991-944D-4D0A-BFA2-DFD9A30243EA

P50

Q34426346-8BB52EE0-DBDB-4041-8C69-ED9970D9696E

P577

Q34426346-94068C32-80F8-4F08-B473-030A914E38F1

P5875

Q34426346-BE252097-7CBC-49FF-A918-68BE9C625A25

P698

Q34426346-EEE41C84-D048-4232-842A-42EF5267C0DD

P921

Q34426346-D80048A4-F0B9-489E-B374-B2B530C0B6A9

P932

Q34426346-2F8073F7-27F7-4EEC-A1E1-A9D57EDD920A

P356

AJPRENAL.00153.2010

P1433

American Journal of Physiology - Renal Physiology

P1476

Renal protection in chronic ki ...... on vs. angiotensin II blockade

@en

P2093

Aihua Deng

http://www.w3.org/2001/XMLSchema#string

Joseph Satriano

http://www.w3.org/2001/XMLSchema#string

Mary Ann K Arndt

http://www.w3.org/2001/XMLSchema#string

Prabhleen Singh

http://www.w3.org/2001/XMLSchema#string

Roland C Blantz

http://www.w3.org/2001/XMLSchema#string

Scott Thomson

http://www.w3.org/2001/XMLSchema#string

Tong Tang

http://www.w3.org/2001/XMLSchema#string

P2860

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation

A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation

Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients

Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy.

The iron(II) and 2-oxoacid-dependent dioxygenases and their role in metabolism.

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

Nitric oxide inhibition of mitochondrial respiration and its role in cell death.

The role of iron and 2-oxoglutarate oxygenases in signalling.

Regulation of oxygen utilization by angiotensin II in chronic kidney disease.

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology.

P304

F1365-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00153.2010

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

299

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46820323

http://www.w3.org/2001/XMLSchema#string

P698

20881034

http://www.w3.org/2001/XMLSchema#string

P921

P932

3006314

http://www.w3.org/2001/XMLSchema#string